Alterity Therapeutics (NASDAQ: ATHE) is a clinical-stage biopharmaceutical company focused on developing novel treatments for debilitating rare neurological and mitochondrial diseases. Originally founded in Australia, the company operates research and clinical development programs in North America, Europe and Asia Pacific. Alterity’s lead investigational therapy, elamipretide, is a first-in-class mitochondria-targeting peptide designed to improve cellular energy production and membrane stability. The company is advancing elamipretide through multiple clinical trials spanning primary mitochondrial myopathy, Barth syndrome and age-related cognitive disorders.
In addition to its flagship program, Alterity maintains preclinical research in neurodegenerative conditions characterized by mitochondrial dysfunction and oxidative stress. The company leverages its proprietary drug delivery platforms and biomarker strategies to optimize clinical trial design and accelerate regulatory approval pathways. Alterity’s scientific team collaborates with leading academic centres and patient advocacy groups to better understand disease mechanisms and refine patient selection criteria, underscoring its commitment to personalized medicine.
Alterity Therapeutics serves a global patient population, with corporate headquarters in Sydney, Australia and a substantial presence in Boston, Massachusetts, where it conducts regulatory and business development activities. The company’s European operations are based in London, facilitating clinical trial enrollment and partnerships across the United Kingdom and continental Europe. This multi-regional footprint enables Alterity to engage with diverse regulatory agencies and to position its therapies for broad international registration.
Underpinning Alterity’s programs is a leadership team with deep expertise in drug development, regulatory affairs and commercialization within the orphan and rare disease sector. The board and executive officers bring decades of experience from both large biopharmaceutical firms and agile biotech ventures, guiding the company’s strategic vision as it advances toward clinical milestones. Alterity remains focused on delivering transformative therapies to patients with limited treatment options, driven by rigorous science and a patient-centric approach.
AI Generated. May Contain Errors.
Free ATHE Stock Alerts